Literature DB >> 18559538

Role of PELP1/MNAR signaling in ovarian tumorigenesis.

Chakravarty Dimple1, Sujit S Nair, Rajib Rajhans, Perla R Pitcheswara, Jinsong Liu, Seetharaman Balasenthil, Xiao-Feng Le, Matthew E Burow, Nelly Auersperg, Rajeshwar Rao Tekmal, Russell R Broaddus, Ratna K Vadlamudi.   

Abstract

Emerging evidence suggests that nuclear receptor (NR) coregulators have potential to act as master genes and their deregulation can promote oncogenesis. Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1/MNAR) is a novel NR coregulator. Its expression is deregulated in hormone-driven cancers. However, the role of PELP1/MNAR in ovarian cancer progression remains unknown. Analysis of serial analysis of gene expression data suggested deregulation of PELP1/MNAR expression in ovarian tumors. Western analysis of PELP1/MNAR in normal and serous ovarian tumor tissues showed 3- to 4-fold higher PELP1/MNAR expression in serous tumors compared with normal ovarian tissues. To examine the significance of PELP1/MNAR in ovarian cancer progression, we have generated model cells that overexpress PELP1/MNAR and ovarian cancer cells in which PELP1/MNAR expression is down-regulated by stable expression of PELP1/MNAR-specific shRNA. Down-regulation of PELP1/MNAR in cancerous ovarian model cells (OVCAR3) resulted in reduced proliferation, affected the magnitude of c-Src and protein kinase B (AKT) signaling, and reduced tumorigenic potential of ovarian cancer cells in a nude mouse model. PELP1/MNAR overexpression in nontumorigenic immortalized surface epithelial cells (IOSE cells) promoted constitutive activation of c-Src and AKT signaling pathways and promoted anchorage-independent growth. Immunohistochemical studies using human ovarian cancer tissue arrays (n = 123) showed that PELP1/MNAR is 2- to 3-fold overexpressed in 60% of ovarian tumors, and PELP1/MNAR deregulation occurs in all different types of ovarian cancer. Collectively, these results suggest that PELP1/MNAR signaling plays a role in ovarian cancer cell proliferation and survival, and that its expression is deregulated in ovarian carcinomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559538     DOI: 10.1158/0008-5472.CAN-07-5698

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

1.  Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer.

Authors:  Lin Yang; Preethi Ravindranathan; Meera Ramanan; Payal Kapur; Stephen R Hammes; Jer-Tsong Hsieh; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2012-03-08

2.  Inhibition of mTOR signaling reduces PELP1-mediated tumor growth and therapy resistance.

Authors:  Vijay K Gonugunta; Gangadhara R Sareddy; Samaya Rajeshwari Krishnan; Valerie Cortez; Sudipa Saha Roy; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2014-03-31       Impact factor: 6.261

Review 3.  Estrogen effects on the brain: actions beyond the hypothalamus via novel mechanisms.

Authors:  Bruce S McEwen; Keith T Akama; Joanna L Spencer-Segal; Teresa A Milner; Elizabeth M Waters
Journal:  Behav Neurosci       Date:  2012-02       Impact factor: 1.912

4.  Significance of ER-Src axis in hormonal therapy resistance.

Authors:  Sreeram Vallabhaneni; Binoj C Nair; Valerie Cortez; Rambabu Challa; Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  Breast Cancer Res Treat       Date:  2010-12-24       Impact factor: 4.872

5.  Regulation of aromatase induction by nuclear receptor coregulator PELP1.

Authors:  Ratna K Vadlamudi; Rajib Rajhans; Dimple Chakravarty; Binoj C Nair; Sujit S Nair; Dean B Evans; Shiuan Chen; Rajeshwar Rao Tekmal
Journal:  J Steroid Biochem Mol Biol       Date:  2009-09-30       Impact factor: 4.292

6.  PELP1 signaling contributes to medulloblastoma progression by regulating the NF-κB pathway.

Authors:  Yiliao Luo; Mengxing Li; Uday P Pratap; Suryavathi Viswanadhapalli; Junhao Liu; Prabhakar P Venkata; Kristin A Altwegg; Bridgitte E Palacios; Xiaonan Li; Yihong Chen; Manjeet K Rao; Andrew J Brenner; Gangadhara R Sareddy; Ratna K Vadlamudi
Journal:  Mol Carcinog       Date:  2019-12-24       Impact factor: 4.784

7.  The SUMO system controls nucleolar partitioning of a novel mammalian ribosome biogenesis complex.

Authors:  Elisabeth Finkbeiner; Markus Haindl; Stefan Muller
Journal:  EMBO J       Date:  2011-02-15       Impact factor: 11.598

Review 8.  Minireview: Deciphering the Cellular Functions of PELP1.

Authors:  Preethi Ravindranathan; Carol A Lange; Ganesh V Raj
Journal:  Mol Endocrinol       Date:  2015-07-09

Review 9.  PELP1: A novel therapeutic target for hormonal cancers.

Authors:  Dimple Chakravarty; Rajeshwar Rao Tekmal; Ratna K Vadlamudi
Journal:  IUBMB Life       Date:  2010-03       Impact factor: 3.885

Review 10.  Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways.

Authors:  Emily M Fox; Josefa Andrade; Margaret A Shupnik
Journal:  Steroids       Date:  2008-11-05       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.